Neurocrine Biosciences, Inc. (NBIX)
USD 109.68
(2.9%)
USD 109.68
(2.9%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 250.9 Million USD | 0.76% |
| 2022 | 249 Million USD | 26.46% |
| 2021 | 196.9 Million USD | -38.26% |
| 2020 | 318.9 Million USD | 45.52% |
| 2019 | 219.14 Million USD | 493.98% |
| 2018 | 36.89 Million USD | 128.09% |
| 2017 | -131.36 Million USD | 10.86% |
| 2016 | -147.37 Million USD | -56.44% |
| 2015 | -94.2 Million USD | -46.25% |
| 2014 | -64.41 Million USD | -29.66% |
| 2013 | -49.67 Million USD | -3530.8% |
| 2012 | 1.44 Million USD | -95.73% |
| 2011 | 33.92 Million USD | 347.21% |
| 2010 | -13.72 Million USD | 74.43% |
| 2009 | -53.67 Million USD | 38.52% |
| 2008 | -87.29 Million USD | 58.87% |
| 2007 | -212.24 Million USD | -87.3% |
| 2006 | -113.31 Million USD | -351.97% |
| 2005 | -25.07 Million USD | 52.09% |
| 2004 | -52.33 Million USD | 10.98% |
| 2003 | -58.78 Million USD | 43.26% |
| 2002 | -103.61 Million USD | -136.12% |
| 2001 | -43.88 Million USD | -23.26% |
| 2000 | -35.6 Million USD | -78.9% |
| 1999 | -19.9 Million USD | -60.48% |
| 1998 | -12.4 Million USD | -2580.0% |
| 1997 | 500 Thousand USD | -82.76% |
| 1996 | 2.9 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 105.3 Million USD | -29.94% |
| 2024 Q2 | 147.9 Million USD | 40.46% |
| 2024 Q3 | 183.8 Million USD | 24.27% |
| 2023 Q1 | -114.2 Million USD | -210.44% |
| 2023 Q4 | 150.3 Million USD | 6.44% |
| 2023 FY | 250.9 Million USD | 0.76% |
| 2023 Q3 | 141.2 Million USD | 91.85% |
| 2023 Q2 | 73.6 Million USD | 164.45% |
| 2022 Q4 | 103.4 Million USD | 17.77% |
| 2022 FY | 249 Million USD | 26.46% |
| 2022 Q2 | 54.7 Million USD | 1664.52% |
| 2022 Q3 | 87.8 Million USD | 60.51% |
| 2022 Q1 | 3.1 Million USD | 108.54% |
| 2021 Q1 | 31.5 Million USD | -56.13% |
| 2021 Q4 | -36.3 Million USD | -181.57% |
| 2021 Q3 | 44.5 Million USD | -29.14% |
| 2021 Q2 | 62.8 Million USD | 99.37% |
| 2021 FY | 196.9 Million USD | -38.26% |
| 2020 Q2 | 76.6 Million USD | 30.05% |
| 2020 Q4 | 71.8 Million USD | 262.08% |
| 2020 FY | 318.9 Million USD | 45.52% |
| 2020 Q1 | 58.9 Million USD | 20.7% |
| 2020 Q3 | -44.3 Million USD | -157.83% |
| 2019 Q2 | 34.46 Million USD | 134.12% |
| 2019 FY | 219.14 Million USD | 493.98% |
| 2019 Q1 | -100.99 Million USD | -561.79% |
| 2019 Q3 | 90.09 Million USD | 161.45% |
| 2019 Q4 | 48.8 Million USD | -45.84% |
| 2018 FY | 36.89 Million USD | 128.09% |
| 2018 Q3 | 54.32 Million USD | 3033.21% |
| 2018 Q4 | 21.87 Million USD | -59.74% |
| 2018 Q1 | -37.44 Million USD | -416.44% |
| 2018 Q2 | -1.85 Million USD | 95.05% |
| 2017 Q2 | -57.26 Million USD | 28.35% |
| 2017 Q4 | 11.83 Million USD | 297.4% |
| 2017 FY | -131.36 Million USD | 10.86% |
| 2017 Q3 | -5.99 Million USD | 89.53% |
| 2017 Q1 | -79.93 Million USD | -72.82% |
| 2016 Q3 | -38.43 Million USD | 8.11% |
| 2016 Q1 | -20.85 Million USD | 32.17% |
| 2016 Q2 | -41.82 Million USD | -100.55% |
| 2016 FY | -147.37 Million USD | -56.44% |
| 2016 Q4 | -46.25 Million USD | -20.33% |
| 2015 Q2 | -25.32 Million USD | -1006.73% |
| 2015 Q4 | -30.74 Million USD | 14.22% |
| 2015 Q1 | -2.28 Million USD | 88.82% |
| 2015 FY | -94.2 Million USD | -46.25% |
| 2015 Q3 | -35.84 Million USD | -41.55% |
| 2014 Q3 | -16.85 Million USD | -17.38% |
| 2014 FY | -64.41 Million USD | -29.66% |
| 2014 Q4 | -20.46 Million USD | -21.42% |
| 2014 Q2 | -14.36 Million USD | -12.86% |
| 2014 Q1 | -12.72 Million USD | -10.36% |
| 2013 FY | -49.67 Million USD | -3530.8% |
| 2013 Q4 | -11.53 Million USD | 3.96% |
| 2013 Q3 | -12 Million USD | 8.82% |
| 2013 Q2 | -13.16 Million USD | -1.48% |
| 2013 Q1 | -12.97 Million USD | -251.19% |
| 2012 Q3 | -3.96 Million USD | -187.1% |
| 2012 Q4 | 8.58 Million USD | 316.61% |
| 2012 FY | 1.44 Million USD | -95.73% |
| 2012 Q2 | -1.38 Million USD | 22.99% |
| 2012 Q1 | -1.79 Million USD | -500.89% |
| 2011 Q3 | 30.44 Million USD | 2677.37% |
| 2011 Q4 | 447 Thousand USD | -98.53% |
| 2011 FY | 33.92 Million USD | 347.21% |
| 2011 Q1 | 1.93 Million USD | 1603.1% |
| 2011 Q2 | 1.09 Million USD | -43.48% |
| 2010 Q4 | -129 Thousand USD | -105.23% |
| 2010 Q3 | 2.46 Million USD | 141.87% |
| 2010 FY | -13.72 Million USD | 74.43% |
| 2010 Q2 | -5.89 Million USD | 42.08% |
| 2010 Q1 | -10.16 Million USD | -13.24% |
| 2009 Q1 | -19.12 Million USD | 37.74% |
| 2009 FY | -53.67 Million USD | 38.52% |
| 2009 Q3 | -9.72 Million USD | 38.63% |
| 2009 Q4 | -8.98 Million USD | 7.64% |
| 2009 Q2 | -15.84 Million USD | 17.16% |
| 2008 Q2 | -20.11 Million USD | 3.11% |
| 2008 Q4 | -30.71 Million USD | -95.59% |
| 2008 FY | -87.29 Million USD | 58.87% |
| 2008 Q1 | -20.76 Million USD | 83.85% |
| 2008 Q3 | -15.7 Million USD | 21.94% |
| 2007 FY | -212.24 Million USD | -87.3% |
| 2007 Q1 | -27.27 Million USD | -67.71% |
| 2007 Q4 | -128.59 Million USD | -346.1% |
| 2007 Q3 | -28.82 Million USD | -4.64% |
| 2007 Q2 | -27.54 Million USD | -1.0% |
| 2006 Q2 | -29.26 Million USD | -6.05% |
| 2006 Q4 | -16.26 Million USD | 59.54% |
| 2006 FY | -113.31 Million USD | -351.97% |
| 2006 Q3 | -40.19 Million USD | -37.36% |
| 2006 Q1 | -27.59 Million USD | -12.2% |
| 2005 FY | -25.07 Million USD | 52.09% |
| 2005 Q3 | 25.12 Million USD | 501.81% |
| 2005 Q1 | -19.34 Million USD | 8.67% |
| 2005 Q2 | -6.25 Million USD | 67.68% |
| 2005 Q4 | -24.59 Million USD | -197.9% |
| 2004 FY | -52.33 Million USD | 10.98% |
| 2004 Q1 | -14.73 Million USD | 15.2% |
| 2004 Q2 | -13.38 Million USD | 9.1% |
| 2004 Q3 | -3.03 Million USD | 77.36% |
| 2004 Q4 | -21.18 Million USD | -598.91% |
| 2003 Q2 | -12.49 Million USD | 18.64% |
| 2003 FY | -58.78 Million USD | 43.26% |
| 2003 Q3 | -13.57 Million USD | -8.68% |
| 2003 Q4 | -17.37 Million USD | -27.97% |
| 2003 Q1 | -15.35 Million USD | 62.8% |
| 2002 Q3 | -22.5 Million USD | -2.18% |
| 2002 FY | -103.61 Million USD | -136.12% |
| 2002 Q4 | -41.27 Million USD | -83.43% |
| 2002 Q2 | -22.02 Million USD | -23.56% |
| 2002 Q1 | -17.82 Million USD | -15.69% |
| 2001 Q2 | -15.59 Million USD | -10.75% |
| 2001 Q3 | 1.19 Million USD | 107.65% |
| 2001 FY | -43.88 Million USD | -23.26% |
| 2001 Q1 | -14.07 Million USD | -24.48% |
| 2001 Q4 | -15.4 Million USD | -1391.2% |
| 2000 FY | -35.6 Million USD | -78.9% |
| 2000 Q2 | -7.38 Million USD | -2.13% |
| 2000 Q4 | -11.31 Million USD | -16.78% |
| 2000 Q3 | -9.68 Million USD | -31.23% |
| 2000 Q1 | -7.22 Million USD | -44.52% |
| 1999 Q1 | -4.5 Million USD | -650.0% |
| 1999 Q2 | -5.3 Million USD | -17.78% |
| 1999 Q3 | -5 Million USD | 5.66% |
| 1999 FY | -19.9 Million USD | -60.48% |
| 1999 Q4 | -5 Million USD | 0.0% |
| 1998 Q2 | -3.9 Million USD | -62.5% |
| 1998 Q1 | -2.4 Million USD | -84.62% |
| 1998 FY | -12.4 Million USD | -2580.0% |
| 1998 Q4 | -600 Thousand USD | 88.89% |
| 1998 Q3 | -5.4 Million USD | -38.46% |
| 1997 Q1 | 3.2 Million USD | -3.03% |
| 1997 Q3 | -400 Thousand USD | 55.56% |
| 1997 Q4 | -1.3 Million USD | -225.0% |
| 1997 FY | 500 Thousand USD | -82.76% |
| 1997 Q2 | -900 Thousand USD | -128.13% |
| 1996 Q1 | -200 Thousand USD | 0.0% |
| 1996 FY | 2.9 Million USD | 0.0% |
| 1996 Q2 | 1.3 Million USD | 750.0% |
| 1996 Q3 | -1.5 Million USD | -215.38% |
| 1996 Q4 | 3.3 Million USD | 320.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -155.56 Million USD | 261.285% |
| Theratechnologies Inc. | -10.62 Million USD | 2460.967% |
| Safety Shot Inc | -12.18 Million USD | 2159.233% |
| Cosmos Health Inc. | -21.83 Million USD | 1249.272% |
| Cronos Group Inc. | -81.37 Million USD | 408.324% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | -20.027% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 740.819% |
| Organogenesis Holdings Inc. | 12.52 Million USD | -1903.194% |
| Universe Pharmaceuticals INC | -3.52 Million USD | 7214.15% |
| ProPhase Labs, Inc. | -21.61 Million USD | 1260.875% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 5437.162% |
| Dynavax Technologies Corporation | -37.02 Million USD | 777.595% |
| Radius Health, Inc. | -3.92 Million USD | 6492.357% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | 10075.282% |
| Alvotech | -354.86 Million USD | 170.704% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 5343.142% |
| Alpha Teknova, Inc. | -35.56 Million USD | 805.509% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 257.422% |
| SCYNEXIS, Inc. | 72.66 Million USD | -245.264% |
| Harrow Health, Inc. | 580 Thousand USD | -43158.621% |
| Biofrontera Inc. | -22.67 Million USD | 1206.407% |
| DURECT Corporation | -36.88 Million USD | 780.241% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 4861.814% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | -434.159% |
| OptiNose, Inc. | -22.74 Million USD | 1202.954% |
| RedHill Biopharma Ltd. | 12.63 Million USD | -1886.225% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 1761.369% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 4139.725% |
| SIGA Technologies, Inc. | 83.62 Million USD | -200.044% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | -2588.887% |
| Shineco, Inc. | -17.06 Million USD | 1570.186% |
| Phibro Animal Health Corporation | 53.31 Million USD | -370.599% |
| Procaps Group S.A. | 52.32 Million USD | -379.512% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 3043.799% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | 5396.908% |
| Viatris Inc. | 766.2 Million USD | 67.254% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 5343.142% |
| Rockwell Medical, Inc. | -6.67 Million USD | 3861.619% |
| Incannex Healthcare Limited | -30.04 Million USD | 935.192% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 4875.409% |
| Tilray Brands, Inc. | -174.74 Million USD | 243.581% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | -50.275% |
| PetIQ, Inc. | 60.01 Million USD | -318.062% |
| Silver Spike Investment Corp. | 7.34 Million USD | -3318.205% |
| Journey Medical Corporation | -2.07 Million USD | 12203.232% |
| Alimera Sciences, Inc. | -1.47 Million USD | 17156.424% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 1942.501% |
| Assertio Holdings, Inc. | -243.53 Million USD | 203.024% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 4358.042% |
| Embecta Corp. | 221.5 Million USD | -13.273% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 1351.368% |
| Procaps Group, S.A. | 38.97 Million USD | -543.779% |
| PainReform Ltd. | -9.58 Million USD | 2717.905% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 282.011% |
| Hempacco Co., Inc. | -8.81 Million USD | 2947.163% |
| Talphera, Inc. | -16.88 Million USD | 1585.582% |
| Pacira BioSciences, Inc. | 87.67 Million USD | -186.171% |
| Alvotech | -354.86 Million USD | 170.704% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 31.193% |
| Kamada Ltd. | 10.06 Million USD | -2393.045% |
| Indivior PLC | -4 Million USD | 6372.5% |
| Currenc Group, Inc. | -6.64 Million USD | 3875.325% |
| Evoke Pharma, Inc. | -7.43 Million USD | 3476.446% |
| Flora Growth Corp. | -50.35 Million USD | 598.272% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 1351.368% |
| Evolus, Inc. | -49.23 Million USD | 609.618% |
| HUTCHMED (China) Limited | 18.37 Million USD | -1265.442% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | -27.369% |
| Akanda Corp. | -10.05 Million USD | 2596.176% |